A 29-year-old man living with HIV on tenofovir alafenamide (TAF)/emtricitabine + dolutegravir (CD4 298, HIV RNA <20 cps/ml) develops pulmonary TB.
The plan is to start empiric INH, RIF, PZA, and ETH pending mycobacterial susceptibilities.
How do you manage his ART regimen?
A. Continue current regimen
B. Change dolutegravir to darunavir/ritonavir
C. Change dolutegravir to elvitegravir
D. Double the dose of dolutegravir
www.idbrcourse.org/ © 2024 IDBR LLC | All Rights Reserved
